Compare SRL & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRL | SEER |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.0M | 111.4M |
| IPO Year | 1996 | 2020 |
| Metric | SRL | SEER |
|---|---|---|
| Price | $8.44 | $1.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.8K | ★ 399.6K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 12.08% | N/A |
| EPS Growth | N/A | ★ 9.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,578,000.00 |
| Revenue This Year | N/A | $2.14 |
| Revenue Next Year | N/A | $25.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.99 |
| 52 Week Low | $5.13 | $1.62 |
| 52 Week High | $10.39 | $2.41 |
| Indicator | SRL | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 44.11 |
| Support Level | $5.37 | $1.71 |
| Resistance Level | $9.60 | $1.97 |
| Average True Range (ATR) | 0.30 | 0.08 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 27.77 | 26.14 |
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.